BACKGROUND: The induction of beige adipocytes in s.c. white adipose tissue (WAT) depots of humans is postulated to improve glucose and lipid metabolism in obesity. The ability of obese, insulin-resistant humans to induce beige adipose tissue is unknown. METHODS: We exposed lean and obese research participants to cold (30-minute ice pack application each day for 10 days of the upper thigh) or treated them with the β3 agonist mirabegron. We determined beige adipose marker expression by IHC and quantitative PCR, and we analyzed mitochondrial bioenergetics and UCP activity with an Oxytherm system. RESULTS: Cold significantly induced UCP1 and TMEM26 protein in both lean and obese subjects, and this response was not associated with age. Interestingly, these proteins increased to the same extent in s.c. WAT of the noniced contralateral leg, indicating a crossover effect. We further analyzed the bioenergetics of purified mitochondria from the abdominal s.c. WAT of cold-treated subjects and determined that repeat ice application significantly increased uncoupled respiration, consistent with the UCP1 protein induction and subsequent activation. Cold also increased State 3 and maximal respiration, and this effect on mitochondrial bioenergetics was stronger in summer than winter. Chronic treatment (10 weeks; 50 mg/day) with the β3 receptor agonist mirabegron induces UCP1, TMEM26, CIDEA, and phosphorylation of HSL on serine660 in obese subjects. CONCLUSION: Cold or β3 agonists cause the induction of beige adipose tissue in human s.c. WAT; this phenomenon may be exploited to increase beige adipose in older, insulin-resistant, obese individuals. TRIAL REGISTRATION: Clinicaltrials.gov NCT02596776, NCT02919176. FUNDING: NIH (DK107646, DK112282, P20GM103527, and by CTSA grant UL1TR001998).
RCT Entities:
BACKGROUND: The induction of beige adipocytes in s.c. white adipose tissue (WAT) depots of humans is postulated to improve glucose and lipid metabolism in obesity. The ability of obese, insulin-resistant humans to induce beige adipose tissue is unknown. METHODS: We exposed lean and obese research participants to cold (30-minute ice pack application each day for 10 days of the upper thigh) or treated them with the β3 agonist mirabegron. We determined beige adipose marker expression by IHC and quantitative PCR, and we analyzed mitochondrial bioenergetics and UCP activity with an Oxytherm system. RESULTS: Cold significantly induced UCP1 and TMEM26 protein in both lean and obese subjects, and this response was not associated with age. Interestingly, these proteins increased to the same extent in s.c. WAT of the noniced contralateral leg, indicating a crossover effect. We further analyzed the bioenergetics of purified mitochondria from the abdominal s.c. WAT of cold-treated subjects and determined that repeat ice application significantly increased uncoupled respiration, consistent with the UCP1 protein induction and subsequent activation. Cold also increased State 3 and maximal respiration, and this effect on mitochondrial bioenergetics was stronger in summer than winter. Chronic treatment (10 weeks; 50 mg/day) with the β3 receptor agonist mirabegron induces UCP1, TMEM26, CIDEA, and phosphorylation of HSL on serine660 in obese subjects. CONCLUSION: Cold or β3 agonists cause the induction of beige adipose tissue in human s.c. WAT; this phenomenon may be exploited to increase beige adipose in older, insulin-resistant, obese individuals. TRIAL REGISTRATION: Clinicaltrials.gov NCT02596776, NCT02919176. FUNDING: NIH (DK107646, DK112282, P20GM103527, and by CTSA grant UL1TR001998).
Authors: Leanne M Redman; Lilian de Jonge; Xiaobing Fang; Betsy Gamlin; David Recker; Frank L Greenway; Steven R Smith; Eric Ravussin Journal: J Clin Endocrinol Metab Date: 2006-11-21 Impact factor: 5.958
Authors: Kristin I Stanford; Roeland J W Middelbeek; Kristy L Townsend; Ding An; Eva B Nygaard; Kristen M Hitchcox; Kathleen R Markan; Kazuhiro Nakano; Michael F Hirshman; Yu-Hua Tseng; Laurie J Goodyear Journal: J Clin Invest Date: 2012-12-10 Impact factor: 14.808
Authors: Patrick G Sullivan; Nancy A Rippy; Kristina Dorenbos; Rachele C Concepcion; Aakash K Agarwal; Jong M Rho Journal: Ann Neurol Date: 2004-04 Impact factor: 10.422
Authors: Brian S Finlin; Beibei Zhu; Amy L Confides; Philip M Westgate; Brianna D Harfmann; Esther E Dupont-Versteegden; Philip A Kern Journal: Diabetes Date: 2017-03-01 Impact factor: 9.461
Authors: Maria Chondronikola; Elena Volpi; Elisabet Børsheim; Craig Porter; Palam Annamalai; Sven Enerbäck; Martin E Lidell; Manish K Saraf; Sebastien M Labbe; Nicholas M Hurren; Christina Yfanti; Tony Chao; Clark R Andersen; Fernando Cesani; Hal Hawkins; Labros S Sidossis Journal: Diabetes Date: 2014-07-23 Impact factor: 9.461
Authors: Philip A Kern; Brian S Finlin; Dorothy Ross; Tania Boyechko; Beibei Zhu; Neile Grayson; Robert Sims; Jeffrey S Bland Journal: J Endocr Soc Date: 2017-04-21
Authors: Kong Y Chen; Robert J Brychta; Zahraa Abdul Sater; Thomas M Cassimatis; Cheryl Cero; Laura A Fletcher; Nikita S Israni; James W Johnson; Hannah J Lea; Joyce D Linderman; Alana E O'Mara; Kenneth Y Zhu; Aaron M Cypess Journal: J Biol Chem Date: 2019-12-30 Impact factor: 5.157
Authors: Alana E O'Mara; James W Johnson; Joyce D Linderman; Robert J Brychta; Suzanne McGehee; Laura A Fletcher; Yael A Fink; Devika Kapuria; Thomas M Cassimatis; Nathan Kelsey; Cheryl Cero; Zahraa Abdul Sater; Francesca Piccinini; Alison S Baskin; Brooks P Leitner; Hongyi Cai; Corina M Millo; William Dieckmann; Mary Walter; Norman B Javitt; Yaron Rotman; Peter J Walter; Marilyn Ader; Richard N Bergman; Peter Herscovitch; Kong Y Chen; Aaron M Cypess Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Ildiko Kasza; Jens-Peter Kühn; Henry Völzke; Diego Hernando; Yaohui G Xu; John W Siebert; Angela L F Gibson; C-L Eric Yen; David W Nelson; Ormond A MacDougald; Nicole E Richardson; Dudley W Lamming; Philip A Kern; C M Alexander Journal: J Physiol Date: 2021-04-15 Impact factor: 5.182